Cover Image

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators

Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter pylori infections. Tegoprazan is mainly metabolized by cytochrome P450 (CYP) 3A4. Considering the therapeutic indications, tegopra...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lien Thi Ngo (Author), Jaeyeon Lee (Author), Hwi-yeol Yun (Author), Jung-woo Chae (Author)
Format:	Book
Published:	MDPI AG, 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug-Drug Interaction between Rivaroxaban and Carbamazepine in Humans
by: Lien Thi Ngo, et al.
Published: (2023)

Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
by: Deok Yong Yoon, et al.
Published: (2021)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
by: Lien Thi Ngo, et al.
Published: (2022)

Prediction of the Drug-Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
by: Zhuodu Wei, et al.
Published: (2023)

Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models
by: Hyo-jeong Ryu, et al.
Published: (2021)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators
by: Fatima Zahra Marok, et al.
Published: (2023)

The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis
by: Quyen Thi Tran, et al.
Published: (2022)

Fine-tuning of BERT Model to Accurately Predict Drug-Target Interactions
by: Hyeunseok Kang, et al.
Published: (2022)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020)

Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2023)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
by: Thomas Wendl, et al.
Published: (2022)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene-Drug-Drug Interactions
by: Flavia Storelli, et al.
Published: (2019)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
by: Takashi Ueno, et al.
Published: (2021)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions
by: Johanna Weiss, et al.
Published: (2016)

A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators
by: Yiting Yang, et al.
Published: (2021)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
by: Deok Y. Yoon, et al.
Published: (2021)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021)

Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine
by: Lara Marques, et al.
Published: (2023)

PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
by: Jayaprakasam Bolleddula, et al.
Published: (2021)

Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
by: Caifu Xue, et al.
Published: (2017)

Prediction of the Impact of CYP2C19 Polymorphism on Drug-Drug Interaction between Voriconazole and Tacrolimus Using Physiologically-Based Pharmacokinetic Modelling
by: Zhi-Ping Jin, et al.
Published: (2023)

Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters
by: Aline Barth, et al.
Published: (2023)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling
by: Laura Maria Fuhr, et al.
Published: (2022)

Fractal Kinetic Implementation in Population Pharmacokinetic Modeling
by: Woojin Jung, et al.
Published: (2023)

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations
by: Hyeon-Cheol Jeong, et al.
Published: (2022)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
by: Fatima Zahra Marok, et al.
Published: (2021)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug-drug-gene interaction network
by: Denise Feick, et al.
Published: (2023)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
by: Hannah Britz, et al.
Published: (2019)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2022)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
by: Sejung Hwang, et al.
Published: (2021)

Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling
by: Taeheon Kim, et al.
Published: (2024)

A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions
by: Denise Türk, et al.
Published: (2020)

Prediction of Pharmacokinetic Drug–Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling
by: Bu F, et al.
Published: (2024)

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
by: Darcy J. Mulford, et al.
Published: (2023)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?
by: Shinji Yamazaki, et al.
Published: (2023)

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
by: Simeon Rüdesheim, et al.
Published: (2020)

Clinical Evaluation of Acetaminophen-Galgeuntang Interaction Based on Population Approaches
by: Quyen Thi Tran, et al.
Published: (2020)

Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug-drug interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2024)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict CYP3A-Mediated Drug Interaction between Saxagliptin and Nicardipine: Bridging Rat-to-Human Extrapolation
by: Jeong-Min Lee, et al.
Published: (2024)

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
by: Kun Wang, et al.
Published: (2021)